1. 3100Diamond and Forrester-predicted vs. coronary CTA-observed prevalence of obstructive CAD in patients with stable chest pain: results from the PROMISE trial. (28th August 2018) Authors: Foldyna, B; Karady, J; Banerji, D; Lu, M T; Ferencik, M; Mayrhofer, T; Bittner, D O; Udelson, J E; Fordyce, C B; Meyersohn, N; Emami, H; Douglas, P S; Hoffmann, U Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P190 QVA149 Once Daily Provides Significant Improvements in Lung Function Over 1 Year in Patients with COPD: The Enlighten Study. (19th November 2012) Authors: Dahl, R; Chapman, K; Rudolf, M; Mehta, R; Kho, P; Alagappan, V; Berhane, I; Chen, H; Banerji, D Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A146 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P192 QVA149 once daily provides superior bronchodilation versus indacaterol, glycopyrronium, tiotropium and placebo: the SHINE study. (19th November 2012) Authors: Barnes, N; Bateman, E; Gallagher, N; Green, Y; Horton, R; Henley, M; Banerji, D Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P193 Glycopyrronium once daily provides rapid and sustained bronchodilation and is well tolerated in patients with COPD: the SHINE study. (19th November 2012) Authors: Bateman, E; Hashimoto, S; Gallagher, N; Green, Y; Horton, R; Henley, M; Banerji, D Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P194 Once-Daily QVA149 Provides Superior Bronchodilation and Improves Lung Function Versus Twice-Daily Fluticasone/Salmeterol in COPD Patients: The ILLUMINATE Study. (19th November 2012) Authors: Vogelmeier, C; Bateman, E; Pallante, J; Bryant, H; Alagappan, V; D'Andrea, P; He, E; Banerji, D Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P234 QVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE study. (14th November 2013) Authors: Chapman, KR; Bateman, ED; Gallagher, N; Hu, H; Banerji, D Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P235 Dual-bronchodilation with once-daily QVA149 in patients with moderate-to-severe COPD: overview of the IGNITE program. (14th November 2013) Authors: Price, D; Mezzi, K; Fedele, MJ; Chen, H; Banerji, D Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P236 Superior lung function with once-daily QVA149 translates into improvements in patient-reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE study. (14th November 2013) Authors: D'Urzo, A; Mahler, DA; Decramer, M; Worth, H; White, T; Alagappan, VKT; Gallagher, N; Chen, H; Kulich, K; Banerji, D Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P237 Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. (14th November 2013) Authors: Vogelmeier, C; Bateman, ED; Chen, H; Banerji, D Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P252 Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial. (2nd December 2011) Authors: D'Urzo, A; van Noord, J A; Martin, C; Horton, R; Banerji, D; Lu, Y; Alagappan, V K T; Overend, T Journal: Thorax Issue: Volume 66(2011)Supplement 4 Page Start: A170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗